Bijal Shah MD, MS, emphasizes the positive outcomes of CAR T cell therapy for patients with relapsed refractory conditions, particularly those who have experienced multiple relapses and high tumor burdens. They highlight the success achieved with CAR T therapy, especially after treatment with Blinatumomab (Blina) and Inotuzumab Ozogamicin (I know).
Bijal Shah MD, MS, compares CAR T therapy as a single agent to other immunotherapy approaches and stresses that the combination of these therapies can be transformative, akin to a seat belt and airbag working together for safety. They discuss the data demonstrating improved survival rates with CAR T cells, particularly for patients who had previously failed Blina and I know treatment. They also address challenges related to intercurrent infections and eligibility for CAR T treatment, emphasizing the need for earlier integration of CAR T therapy in the treatment pathway.